Develops antifungal therapies for serious and life-threatening fungal infections, focusing on improving treatment options.
SCYNEXIS, Inc. is a pioneering biotechnology firm based in Jersey City, New Jersey, specializing in the development of advanced treatments for fungal infections within the United States. Notably, the company has introduced BREXAFEMME (ibrexafungerp tablets) to address vulvovaginal candidiasis (VVC), a common fungal condition affecting women. Beyond its current offerings, SCYNEXIS is focused on advancing its lead product candidate, Ibrexafungerp, designed for both oral and intravenous administration. This novel drug shows promise in treating a range of fungal infections, including recurrent VVC, invasive aspergillosis, candidiasis, and refractory fungal infections.
The company's commitment to innovation is underscored by strategic research collaborations with global partners such as Merck Sharp & Dohme Corp., Hansoh Health Technology Co., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC. These alliances aim to accelerate the development and commercialization of ibrexafungerp across various therapeutic applications. Originally founded in 1999 under the name SCYNEXIS Chemistry & Automation, Inc., the company rebranded to SCYNEXIS, Inc. in June 2002, marking a pivotal shift towards biopharmaceutical advancements in fungal disease management.
Headquartered in Jersey City, SCYNEXIS, Inc. continues to drive groundbreaking research and development efforts in the field of antifungal therapeutics. With a robust pipeline and a steadfast commitment to addressing critical medical needs, SCYNEXIS remains at the forefront of innovation, aiming to improve patient outcomes globally through its pioneering treatments.